Trial Profile
Correlation between aqueous VEGF levels and clinical treatment response in ranibizumab treated DME- Identifying and characterizing responders and nonresponders
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Biomarker; Therapeutic Use
- 25 Feb 2020 Status changed from recruiting to completed.
- 14 Feb 2017 New trial record